Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?

AIDS Reviews

Volumn 6, Issue 3, 2004, Pages 169-180

  de Mendoza, Carmen ^a   Sanchez Conde, Matilde ^a   Ribera, Esteve ^b   Domingo, Pere ^c   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

HIV; Hyperlactatemia; Lipoatrophy; Mitochondrial DNA; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

AMINOACIDURIA; ANALYTIC METHOD; ATAXIA; BRAIN DISEASE; CARDIOMYOPATHY; CEREBRAL BLINDNESS; CLINICAL TRIAL; CORRELATION FUNCTION; DIABETES MELLITUS; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA DETERMINATION; DYSTONIA; ENZYME ACTIVITY; FANCONI RENOTUBULAR SYNDROME; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMIANOPIA; HEMIPARESIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; HYPERTRIGLYCERIDEMIA; HYPOPARATHYROIDISM; INTESTINE PSEUDOOBSTRUCTION; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOMATOSIS; LIVER DYSFUNCTION; MIGRAINE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL GENETICS; MITOCHONDRIAL TOXICITY; MUSCLE WEAKNESS; MYOCLONUS; MYOPATHY; OBESITY; OPHTHALMOPLEGIA; OPTIC NERVE ATROPHY; OXYGEN CONSUMPTION; PANCREAS INSUFFICIENCY; PANCREATITIS; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PSYCHOMOTOR RETARDATION; PTOSIS; RETINOPATHY; REVIEW; SCHWARTZ BARTTER SYNDROME; SEIZURE; SHORT STATURE; SIDEROBLASTIC ANEMIA;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, VERTICAL; DNA DAMAGE; DNA, MITOCHONDRIAL; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MITOCHONDRIAL DISEASES; MUTATION; PREGNANCY;

EID: 10044232783     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-30.
2. Walker U, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogues reverse transcriptase inhibitors. AIDS 2002;16:2165-73.
3. Dagan T, Sable C, Bray J, et al. Mitochondrial dysfunction and antiretroviral nucleoside analogues toxicities: what is the evidence? Mitochondrion 2002;1:397-412.
4. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004;18:137-51.
5. Elston T, Wang H, Oster G. Energy transduction in ATP synthase. Nature 1998;391:510-3.
6. Chinnery P, Howell N, Andrews R, Turnbull D. Clinical mitochondrial genetics. J Med Genet 1999;36:425-36.
7. Johnson A, Johnson K. Exoruclease proofreading by human mitochondrial DNA polymerase. J Biol Chem 2001;276:38097-107.
8. Di Mauro S, Schon F. Mitochondrial respiratory chain diseases. N Engl J Med 2003;348:2656-68.
9. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26:43-53.
10. Petersen K, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300:1140-2.
11. Brinkman K, Ter Hofstede H, Burger D, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998;12:1735-44.
12. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505.
13. Brinkman K, Kakuda T. Mitochondrial toxicity of nucleoside reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000;13:5-11.
14. Miller R, Shahmonesh M, Hanna M, et al. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. Antiviral Ther 2003;8:253-7.
15. Lim S, Ponamerev M, Longley M, Copeland W. Structural determinants in human DNA polymerase y account for mitochondrial toxicity from nucleoside analogs. J Mol Biol 2003:329;45-57.
16. Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-65.
17. Martin J, Brown C, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38: 2743-9.
18. Lewis W, Dalakas M. Mitochondrial toxicity of antiretroviral drugs. Nat Med 1995;1:417-22.
19. Kakuda T. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
20. Birkus G, Hitchcock M, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23.
21. Feng J, Murakami E, Zorca S, et al. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′, 3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by HIV-1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother 2004;48:1300-6.
22. Dalakas M, IIIa I, Pezehkpour G, et al. Mitochondrial myopathy caused by long-term zidovudine toxicity. N Engl J Med 1990; 322:1098-105.
23. Arnudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patient with zidovudine-induced myopathy Lancet 1991;337:508-10.
24. Peters B, Winer J, Landon D, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med 1993;86:5-15.
25. Falcó V, Crespo M, Ribera E. Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Coin Pharmacother 2003;4:1321-9.
26. Guo Y, Fung H. Fatal lactic acidosis associated with co-administration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy 2004;24:1089-94.
27. Lonergan J, Havlir D, Barber E, et al. Incidence of symptomalic hyperlactatemia in HIV-infected adults on NRTI. 9th Conference on Retrovirus and Opportunistic Infections. Seattle 2002 [abstract 35].
28. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002;15:23-9.
29. McComsey G, Yau L. Natural history of sustained hyperlactatemia in HIV-infected subjects. 43rd ICAAC. Chicago 2003 [abstract H-1955].
30. McComsey G. Asymptomatic hyperlactatemia: predictive value, natural history and correlates. Antiviral Ther 2004;9:205-12.
31. McComsey G, Lonergan T, Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immun Defic Syndr 2004;37(Suppl):30-5.
32. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-8.
33. Gervasoni C, Ridolfo A, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-72.
34. Heath K, Hogg R, Chan K, et al. Lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort. AIDS 2001;15:231-40.
35. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17(Suppl):141-8.
36. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and HIV infection: Aquitaine cohort, France 1999. Clin Infect Dis 2000;31:1482-7.
37. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy. Clin Infect Dis 2001;32:1045-52.
38. Strawford A, Hellerstein M. Metabolic complications of HIV and AIDS. Curr Infect Dis Rep 2001;3:183-92.
39. Dube M, Johnson D, Currier J, Leedom J. Protease inhibitors associated hyperglycaemia. Lancet 1997;350:713-34.
40. Yarasheski K, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immun Defic Syndr 1999;21:209-16.
41. Martínez E, Mocroft A, García-Viejo M, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
42. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside therapy. AIDS 1999;13:1659-67.
43. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS 2000;14:25-32.
44. García-Benayas T, Blanco F, Gómez-Viera J, et al. Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. AIDS 2002;16:1087-9.
45. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029-36.
46. Moyle G, Baldwin C, Langroudi B, Mandalia S, Gazzard B. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immun Defic Syndr 2003; 33:22-8.
47. Van der Valk M, Casula M, Weverling G, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Thor 2004;9:385-93.
48. Nolan D, Mallal S The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther 2004;9:34-40.
49. Blanco F, García-Benayas T, De la Cruz J, et al. First-line therapy and mitochandrial damage: different nucleosides, different findings. HIV Clin Trials 2003;4:11-9.
50. García-Benayas T, Blanco F, De la Cruz J, et al. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003;17:921-4.
51. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
52. Cote H, Zabrina D, Brumme L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
53. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1 infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003;70:497-505.
54. De Mendoza C, De Ronde A, Smolders K, et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:271-3.
55. Arnoult D, Petit F, Lelievre J, Estaquier J. Mitochondria in HIV-1 induced apoptosis. Biochem Biophys Res Comm 2003;304:561-74.
56. Badley A, Roumier T, Lum J, Kroemer G. Mitochondrion mediated apoptosis in HIV-1 infection. Trends Pharmacol Sci 2003; 24:298-305.
57. Twu C. Cardiomyocytes undergo apoptosis in HIV cardiomyopathy through mitochondrion and death receptor controlled pathways. Proc Natl Acad Sci USA 2002;24:14386-91.
58. Nie Z. HIV protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 2002;9:1172-84.
59. Gahan M, Miller F, Lewin S et al. Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time dolymerase chain reactions. J Clin Virol 2001;22:241-7.
60. Petit C, Mathez D, Barthelemy C, et al. Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immun Defic Syndr 2003;33:461-9.
61. Chiappini F, Teicher E, Saffroy R, et al. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004;84:908-14.
62. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-38
63. Walker U, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didarosine, stavudine, or zalcitabine. Hepatology 2004;39:311-7
64. Lim S, Copeland W. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase γ. J Biol Chem 2001;276:616-23.
65. Walker U, Bickel M, Volksbeck S, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immun Defic Syndr 2002;29:117-21.
66. Miró O, Gómez M, Pedrol E, et al. Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy related lipodystrophy. AIDS 2000;14:1855-7.
67. Zylberberg H, Nalpas B, Pol S, et al. Is there a relationship between hepatitis C virus infection and anti retroviral-associated lipoatrophy? AIDS 2000;14:2055.
68. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus associated hepatocarcinogenesis. Cancer Res 2001;61:4365-70.
69. Shao J, Gao H, Li H, et al. Quantitative detection of common deletion of mitochondrial DNA in hepatocellular carcinoma and hepatocellular nodular hyperplasic. World J Gastroenterol 2004; 10:1560-4.
70. Walker U, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004;39:311-7.
71. De Mendoza C, Sánchez-Conde M, Timmermans E, et al. Mitochondrial DNA depletion in HIV-infected patients is enhanced with chronic hepatitis C and treatment with pegylated interferon plus ribavirin. XV International AIDS Conference Bangkok, July 2004 [abstract MoPeB3313].
72. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-1.
73. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, et al. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1803.
74. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV coinfected patients receiving ribavirin. Antiviral Ther 2004;9:133-8.
75. Balzarini J, Lee C, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′3′-dideoxyrosine against HIV. J Biol Chem 1991; 266:21509-14.
76. García-Benayas T, Blanco F, Soriano V. Weight loss in HIV-intected patients. N Engl J Med 2002;347:1287-8.
77. Duong M, Petit J, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus coinfected patients undergoing antiretroviral therapy. J Acquir Immun Defic Syndr 2001;27:245-50.
78. Lonardo A, Adinolfi L, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
79. Shiramizu B, Shikuma K, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immun Defic Syndr 2003;32:370-4.
80. Divi R, Walker V, Wade N, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004;18:1013-21.
81. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Lancet 1999;354:1084-9.
82. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-85.
83. Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chem Acta 1994;228:35-51.
84. Miró O, Barrientos A, Alonso J, et al. Effects of general anesthetic procedures on mitochondrial function of human skeletal muscle. Eur J Clin Pharmacol 1999;55:35-41.
85. Casademont J, Perea M, López S, et al. Enzymatic diagnosis of oxidative phosphorylation defects on muscle biopsy: better on tissue homogenate or on a mitochondria-enriched suspension? Med Sci Monit 2004;10:49-53.
86. Rustin P, Chretien D, Bourgeron T, et al. Assessment of the mitochondrial respiratory chain. Lancet 1991;338:60.
87. Birch-Machin M, Turnbull D. Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol 2001;65:97-117.
88. Miró O, López S, Pedrol E, et al. Mitochondrial DNA depletion and respiratory chain enzymatic deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antiviral Ther 2003;8:333-8.
89. López S, Miró O, Martínez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antiviral Ther 2004;9:47-55.
90. Miró O, López S, Martínez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004;39:710-6.
91. Martin A, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in HIV-infected patients treated with nucleoside analogue reverse transcriptase inhibitors. Am J Hum Genet 2003;72:549-60.
92. Singh K, Hanne A, Krupp G. Real-time monitoring of RNA and DNA reactions by fluorescence detection. Methods Mol Biol 2004; 252:33-48.
93. De Ronde A, Van Gemen B, Casula M. Decline of mitochondrial DNA during therapy with nucleoside analogue reverse transcriptase inhibitors assessed by a single-tube NASBA simultaneously assaying both mitochondrial and nuclear DNA. XIV International AIDS Conference. Barcelona 2002 [abstract WeOrB1305].
94. Casula M, Do Baar M, Van Gemen B, et al. Therapy with efavirenz + ritonavir boosted indinavir, with or without stavudine after 24 weeks does not decrease mtDNA and mtRNA content of PBMC assessed by single-tube duplex real time NASBA. Antiviral Ther 2002;7:16.
95. Banas B, Kost B, Goebel F. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells. Eur J Med Res 2004;9:371-7.
96. Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 2003;16:5-10.